Skip to main
REPL
REPL logo

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group Inc has significantly raised its probability of approval for its product candidate RP1 in combination with Opdivo for advanced melanoma patients, from 75% to 95%, based on promising clinical trial results showing an objective response rate of approximately 33.6%. The company's focus on in-house manufacturing is expected to provide cost advantages, contributing to favorable gross margins as it prepares for a global supply scale. Additionally, the advancement and global enrollment strategy for the IGNYTE-3 confirmatory trial position Replimune favorably for potential commercial launch by the end of the year, reinforcing the positive outlook for its stock.

Bears say

Replimune Group Inc. is projected to incur a net loss of $2.99 per share for fiscal 2025, indicative of persistent financial challenges. The company faces multiple risks, including potential failure to generate compelling data for its lead candidate RP1, setbacks in pivotal trials, and overall regulatory approval hurdles, all of which could severely impact its growth trajectory. Additionally, the possibility of medium- to long-term dilution risks further compounds the negative outlook surrounding the company's stock, particularly if development is halted due to safety concerns or lack of efficacy.

REPL has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 13 analysts, REPL has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.